The Dystrophic Epidermolysis Bullosa market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Dystrophic Epidermolysis Bullosa: An Overview
Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma.
To date, there is no treatment or cure for EB. EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes.
There are various types and subtypes of EB. As per the most recent classification, EB is broadly classified into EB Simplex (EBS), junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome. DEB is one of the major forms of EB. It is caused by mutations in the COL7A1 gene and may be inherited in an autosomal dominant or autosomal recessive manner depending on the subtype.
Dystrophic Epidermolysis Bullosa Market Key Facts
-
Assessments as per DelveInsight’s analysts show that the total diagnosed prevalent cases of Epidermolysis Bullosa in 7MM were 39,400+ in 2017.
-
In 2017, the diagnosed prevalent cases of Dystrophic Epidermolysis Bullosa in the 7MM was 13,800+.
-
In 2017, there were 8,600+ diagnosed prevalent cases of Dystrophic Epidermolysis Bullosa in the United States.
-
Among the European countries, Germany had the highest diagnosed prevalent population of Dystrophic Epidermolysis Bullosa, followed by the UK. On the other hand, France had the lowest diagnosed prevalent population in 2017.
-
Japan had 1,100+ diagnosed prevalent cases of Dystrophic Epidermolysis Bullosa in 2017.
Dystrophic Epidermolysis Bullosa Market
The pipeline of Dystrophic Epidermolysis Bullosa is robust and promising. To date, there is no cure for Dystrophic Epidermolysis Bullosa and only supportive care is available for the patients. The expected launch of novel therapies will drive the DEB market in the forthcoming years. Also, therapies are being developed for Recessive DEB which will further accelerate the market.
Various associations, institutions, and companies are raising funding for accelerating the development of novel therapies for DEB treatment. These fundings will be supportive of companies to enhance their R&D operations.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Dystrophic Epidermolysis Bullosa market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Dystrophic Epidermolysis Bullosa market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Dystrophic Epidermolysis Bullosa Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Dystrophic Epidermolysis Bullosa Epidemiology Segmentation
-
Total Diagnosed Prevalent Population of Epidermolysis Bullosa (EB)
-
Total Diagnosed Prevalent Population of Dystrophic Epidermolysis Bullosa (DEB)
-
Subtype-specific Diagnosed Prevalent Population of Dystrophic Epidermolysis Bullosa (DEB)
Dystrophic Epidermolysis Bullosa Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dystrophic Epidermolysis Bullosa market or expected to get launched during the study period. The analysis covers Dystrophic Epidermolysis Bullosa market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Dystrophic Epidermolysis Bullosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market
Dystrophic Epidermolysis Bullosa Therapeutics Analysis
Currently, there is no cure for Dystrophic Epidermolysis Bullosa, although considerable progress has been made in testing novel treatments including gene therapy (COL7 encoding gene therapy), as well as cell therapy (use of allogeneic fibroblasts, mesenchymal stromal cells (MSCs), and bone marrow transplantation (BMT)).
Dystrophic Epidermolysis Bullosa Companies operating in the market include:
-
Fibrocell Technologies
-
RegeneRx
-
Amryt Pharma
-
Abeona Therapeutics
-
Krystal Biotech
-
Macular Telangiectasia
And others.
Dystrophic Epidermolysis Bullosa Therapies covered in the report include:
-
FCX-007
-
RGN-137
-
AP-101
-
EB-101
-
Zorblisa
-
Beremagene geperpavec
And many more.
With the expected launch of emerging therapies the therapeutics market landscape of Dystrophic Epidermolysis Bullosa is anticipated to change significantly during the forecasted period.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Dystrophic Epidermolysis Bullosa Competitive Intelligence Analysis
4. Dystrophic Epidermolysis Bullosa Market Overview at a Glance
5. Dystrophic Epidermolysis Bullosa Disease Background and Overview
6. Dystrophic Epidermolysis Bullosa Patient Journey
7. Dystrophic Epidermolysis Bullosa Epidemiology and Patient Population
8. Dystrophic Epidermolysis Bullosa Treatment Algorithm, Current Treatment, and Medical Practices
9. Dystrophic Epidermolysis Bullosa Unmet Needs
10. Key Endpoints of Dystrophic Epidermolysis Bullosa Treatment
11. Dystrophic Epidermolysis Bullosa Marketed Products
12. Dystrophic Epidermolysis Bullosa Emerging Therapies
13. Dystrophic Epidermolysis Bullosa Seven Major Market Analysis
14. Attribute Analysis
15. Dystrophic Epidermolysis Bullosa Market Outlook (7 major markets)
16. Dystrophic Epidermolysis Bullosa Access and Reimbursement Overview
17. KOL Views on the Dystrophic Epidermolysis Bullosa Market.
18. Dystrophic Epidermolysis Bullosa Market Drivers
19. Dystrophic Epidermolysis Bullosa Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Bevacizumab Biosimilars Insight
“Bevacizumab Biosimilar Insight” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. The report also covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/